MedCloud Minute
The MedCloud Minute blog is researched, fact-checked, edited and updated by the editors of MedCloudInsider.com, with writing assistance from AI. To submit your company's press release for consideration, contact [email protected].
Xenocor, a Utah-based medical device company dedicated to transforming surgical visualization, announced it has received a U.S. patent for its next-generation single-use medical borescope technology, designed to improve visualization during minimally invasive procedures. The patented system integrates a lightweight optical sensor and advanced image-processing algorithms, enabling high-resolution imaging without the need for reusable or sterilized components. The company stated that the design reduces the risk of infection and lowers maintenance costs for hospitals and surgical centers.
The patent aligns with healthcare’s shift toward disposable, infection-resistant medical devices, the company said. Xenocor’s approach, which combines affordability with real-time image quality, could appeal to smaller facilities seeking to modernize their surgical imaging without incurring significant capital investments.
Posted by MedCloudInsider Editors on 10/07/20250 comments
WaveBreak Therapeutics, a biopharmaceutical company developing a new class of therapeutics for the treatment of neurodegenerative diseases, has published new data demonstrating that its experimental compound, WTX-607, binds to and reduces alpha-synuclein aggregates in human brain tissue. The findings, shared at the International Congress of Parkinson's Disease and Movement Disorders, suggest that WTX-607 could slow or prevent neurodegeneration associated with Parkinson’s disease and Lewy body dementia. The company stated that the molecule penetrates brain tissue efficiently and has demonstrated efficacy in multiple preclinical models.
The announcement adds to a growing body of research targeting alpha-synuclein, a hallmark protein in Parkinson’s pathology. The success of the preclinical trials positions WTX-607 as a potential treatment for Parkinson's disease and Lewy body dementia.
Posted by MedCloudInsider Editors on 10/07/20250 comments
OutcomeMD has introduced the Patient Experience Data Network, the first data intelligence network powered by patient-reported outcomes (PROs). The platform aggregates de-identified data from healthcare organizations using OutcomeMD’s digital tools to measure how patients feel and function after treatment. Participating sites can benchmark outcomes, compare therapies, and access dashboards that link clinical claims and PRO data for research or value-based care initiatives. The launch aims to collect high-quality data to extract actionable insights that enable innovation and improvements in healthcare.
The Patient Experience Data Network shows patients that they are being heard and that their lived experiences are being recorded for future use, the company said.
Posted by MedCloudInsider Editors on 10/07/20250 comments
Benchling, provider of a cloud-based platform for biotechnology research and development, has launched Benchling AI, a suite of generative and predictive tools built to streamline scientific workflows across drug discovery, biomanufacturing, and genomics. The platform integrates directly with Benchling’s cloud-based data system, enabling researchers to query experiments in natural language, generate molecular annotations, and surface insights from structured and unstructured datasets. Benchling CEO Sajith Wickramasekara stated, "The goal is to put AI in the hands of every scientist and bend the speed and cost curve of making medicines." Benchling AI features agents, including the Deep Research Agent, Data Entry Agent, and Compose Agent, enabling scientists to access models in one place for optimized experiments.
The launch comes amid growing investment in AI for scientific research. Benchling claims its advantage lies in its integration with existing lab workflows, providing scientists with AI assistance within the data platforms they already use. A top 20 biopharma company has already utilized Benchling’s Deep Research Agent, reducing project length by eight months.
Posted by MedCloudInsider Editors on 10/07/20250 comments
Medtronic announced FDA approval of the Altaviva device, designed to treat urge urinary incontinence (UUI). The device is a minimally invasive, implantable tibial neuromodulation (ITNM) therapy inserted near the ankle. Altaviva is intended for patients who do not feel comfortable with invasive therapies, given the potential side effects.
The device is designed to have a 15-year battery lifespan, requiring no daily adjustments. It is MRI compatible and requires only 30 minutes of recharging. Medtronic, which has been investing heavily in connected care, is positioning Altaviva as part of its broader strategy to expand patient access and simplify treatment.
Posted by MedCloudInsider Editors on 09/26/20250 comments
The US Marine Corps has renewed its contract with defense tech company Tagup to continue using its AI-powered logistics platform, Manifest, for battlefield medical support. Manifest replaces legacy systems that often led to expired supplies, overstocked warehouses, or delayed missions. The AI tool is designed to optimize inventory management and accelerate the delivery of critical medical equipment to deployed forces.
The renewal comes as the US Marine Corps aims to adopt a modernized approach to logistics, utilizing AI to ensure speed and precision. By keeping Tagup in its toolkit, the Marine Corps signals confidence in smaller defense tech firms to deliver agile solutions alongside larger contractors. It also ensures that Marines can receive the necessary medical supplies, regardless of the condition.
Posted by MedCloudInsider Editors on 09/26/20250 comments
The Consumer Technology Association (CTA) has announced a new Health AI standard, CTA2135: Performance Verification and Validation for Predictive Health AI Solutions. This standard is designed to ensure predictive AI tools in healthcare are accurate, reliable, and ready for deployment. The announcement was made at the CTA’s Health AI+ event at Hopkins Bloomberg Center.
CTA President Kinsey Fabrizio emphasized how the new standard is aimed at helping developers to fulfill AI’s promise of solving significant challenges that address patient and provider needs.
Also released was a CTA research report titled "AI’s Impact and Opportunity Among Healthcare Practitioners," which finds that although AI adoption in healthcare is still nascent, many clinicians are optimistic about what the tools could do, especially for reducing administrative burden, improving documentation, and freeing up time for patient care. The new CTA-2135 release is another of CTA’s extensive portfolio of health-focused AI standards and research.
Posted by MedCloudInsider Editors on 09/21/20250 comments
Olympus has launched the VISERAS OTV-S500, its newest imaging platform, designed for ear, nose, and throat (ENT) and urological procedures. The system is designed for both office and outpatient settings, offering flexible and rigid endoscope compatibility, along with a built-in lighting system that supports switching between white light, stroboscopy mode, and Narrow Band Imaging (NBI).
A key feature of the VISERA S system is its tight integration with Olympus’s content management tools, including the nCare medical recorder and VaultStream system, enabling clinicians to capture procedural recordings and share data across sites within a facility. Olympus also emphasized that NBI technology has been shown to reduce recurrence in non-muscle invasive bladder cancer (NMIBC) by about 37% over a follow-up period of 1,235 months compared with white light cystoscopy alone. The VISERA S Video is not suitable for cardiac applications, but its main features include improved color, depth, and resolution for a clear view of vascular structures.
Olympus Corporation is a global medical technology company committed to providing minimally invasive treatments to improve patient outcomes with elevated standards of care.
Posted by MedCloudInsider Editors on 09/21/20250 comments
Eleos Health has launched Groups, a feature in its documentation platform aimed at simplifying individual speaker notes from group substance use disorder (SUD) therapy sessions. The new tool automatically produces individual speaker summaries from group sessions, whether in-person or via telehealth, while ensuring privacy standards are met to help organizations maintain compliance and reduce administrative overhead.
The Groups capability works with any EHR system and integrates with Eleos’s existing documentation tools. Audio is processed in real time in a HIPAA-compliant environment; Eleos does not save raw session audio, protecting patient privacy. According to Eleos, the solution helps clinicians generate more than 80% of progress note content, with over 90% of notes submitted within 24 hours, and reduces documentation time by over 70%.
Eleos serves more than 200 organizations and more than 35,000 providers. CEO Alon Joffe said the tool supports scaling group therapy sustainably and improving revenue consistency for SUD treatment entities. The key benefits of Groups will help SUD organizations with a reduction in admin, streamlined documentation and provides support to clinical teams by freeing up time. Eleos will demonstrate the new feature at its Summer Launch Event on September 17.
Posted by MedCloudInsider Editors on 09/21/20250 comments
Intrinsic Therapeutics, a medical technology company, has successfully implanted its Barricaid Annular Closure Device in several patients while they remained awake, marking the first time this procedure has been done without general anesthesia. Dr. Ernest E. Braxton Jr., a neurosurgeon specializing in awake and minimally invasive spine surgery, performed the operations in Vail, Colorado.
The new approach uses local and regional anesthesia, enabling patients to provide real-time feedback during the procedure to confirm that nerve pressure has been relieved. Dr. Braxton has been performing awake surgery for more than a decade. Some benefits include a faster recovery period, reduced pain, and fewer risks commonly associated with general anesthesia, such as nausea or postoperative confusion.
Barricaid is a device designed to reduce reherniation and reoperation rates in patients with significant annular defects following lumbar discectomy surgery. It has been implanted in more than 12,000 patients, with clinical studies, including randomized controlled trials and six single-arm studies.
Posted by MedCloudInsider Editors on 09/21/20250 comments
Lightbeam Health Solutions said on Tuesday it has received Microsoft’s AI Cloud Partner Program Healthcare AI Certified software designation for its population health management platform.
The Dallas-based company, which provides AI-enabled tools and services for care coordination, is one of 10 organizations worldwide to receive the designation. Microsoft’s certification verifies that software meets standards for security, interoperability and performance, and is designed to give healthcare providers confidence in adopting cloud-based AI systems.
Lightbeam said the recognition reinforces its collaboration with Microsoft and supports its strategy of using artificial intelligence to help hospitals, health systems and insurers improve quality of care while lowering costs. The company has offered AI-driven healthcare technologies since 2009 and provides services for accountable care organizations, Medicare Advantage, Medicaid and commercial populations.
Chief Technology Officer Michael Hoxter said the certification demonstrates Lightbeam’s focus on delivering secure, validated technology for value-based care. Microsoft’s worldwide healthcare and life sciences lead, Elena Bonfiglioli, said the designation highlights Lightbeam’s early adoption of AI and ability to deliver results in a tight labor market.
The company recently reported that Saint Peter’s University Hospital used its AI platform to cut emergency department visits by 7%.
Posted by MedCloudInsider Editors on 09/17/20250 comments
U.S. health technology company Tellihealth said on Tuesday it has added new features to its Evelyn platform, which combines remote patient monitoring (RPM) with chronic care management (CCM).
The updates include a dashboard that gives call agents and nurses real-time patient information, templates to guide remote patient assessments, a mobile app for patients to track readings and receive reminders, and a game-based feature to encourage daily participation.
Tellihealth said the enhancements are designed to improve clinical workflows, increase patient engagement, and support integration with electronic health record (EHR) systems.
The company, created through the merger of Accuhealth and Signallamp Health, positions Evelyn as a scalable platform for hospitals, health systems, and clinics. It plans deeper interoperability across care settings to generate more data-driven insights for clinicians and patients.
Chief Technology Officer John Kalivas, who joined in April, is leading development of the next-generation system. Chief Executive Asif Ahmad said the upgrades are aimed at simplifying remote care and improving outcomes through tighter EHR integration.
Posted by MedCloudInsider Editors on 09/17/20250 comments